Acute Erythroid Leukemia: From Molecular Biology to Clinical Outcomes.
Fernandes P, Waldron N, Chatzilygeroudi T, Naji NS, Karantanos T.
Int J Mol Sci. 2024 Jun 6;25(11):6256. doi: 10.3390/ijms25116256.
Acute erythroid leukemia.
Zuo Z, Polski JM, Kasyan A, Medeiros LJ.
Arch Pathol Lab Med. 2010 Sep;134(9):1261-70. doi: 10.5858/2009-0350-RA.1.
Chemotherapeutics for Acute Erythroid Leukemia: Research, Present and Future.
Liao Z, Li J, Wu J, Liu J, Sun S.
Curr Mol Med. 2021;21(10):819-831. doi: 10.2174/1566524021666210121142316.
A History and Current Understanding of Acute Erythroid Leukemia.
Alexander C.
Clin Lymphoma Myeloma Leuk. 2023 Aug;23(8):583-588. doi: 10.1016/j.clml.2023.04.011. Epub 2023 Apr 28.
Modeling acute erythroid leukemia via CRISPR.
Zhang JP, Cheng T.
Blood. 2021 Mar 25;137(12):1565-1567. doi: 10.1182/blood.2020010544.
Pure erythroid leukemia.
Wang W, Wang SA, Medeiros LJ, Khoury JD.
Am J Hematol. 2017 Mar;92(3):292-296. doi: 10.1002/ajh.24626. Epub 2017 Feb 3.
Acute erythroid leukemia is enriched in NUP98 fusions: a report from the Children's Oncology Group.
Chisholm KM, Heerema-McKenney AE, Choi JK, Smith J, Ries RE, Hirsch BA, Raimondi SC, Alonzo TA, Wang YC, Aplenc R, Sung L, Gamis AS, Meshinchi S, Kahwash SB.
Blood Adv. 2020 Dec 8;4(23):6000-6008. doi: 10.1182/bloodadvances.2020002712.
HDAC7 is a potential therapeutic target in acute erythroid leukemia.
Zhang W, Yamamoto K, Chang YH, Yabushita T, Hao Y, Shimura R, Nakahara J, Shikata S, Iida K, Chen Q, Zhang X, Kitamura T, Goyama S.
Leukemia. 2024 Dec;38(12):2614-2627. doi: 10.1038/s41375-024-02394-5. Epub 2024 Sep 15.
Pure erythroid leukemia.
Bain BJ.
Am J Hematol. 2018 Mar;93(3):E75. doi: 10.1002/ajh.25005. Epub 2017 Dec 23.
Re-evaluation of acute erythroid leukemia according to the 2016 WHO classification.
Chen Y, Pourabdollah M, Atenafu EG, Tierens A, Schimmer A, Chang H.
Leuk Res. 2017 Oct;61:39-43. doi: 10.1016/j.leukres.2017.08.011. Epub 2017 Aug 25.
